Starting from the binding mode of allosteric EGFR inhibitor JBJ-04-125-02 and the key pharmacophore of the third-generation EGFR inhibitors, we designed and synthesized a novel series of EGFR inhibitors, represented by (R)-N-(4-((2-aminopyrimidin-4-yl)amino)phenyl)-2-(5-(4-(4-methylpiperazin-1-yl)phenyl)-1-oxoisoindolin-2-yl)-2-phenylacetamide (6q). Docking study demonstrated that top compound 6q spanned
我们从变构
EGFR
抑制剂JBJ-04-125-02的结合模式和第三代
EGFR
抑制剂的关键药效团出发,设计合成了以( R ) -N- (4-为代表的新型
EGFR
抑制剂系列。 ((2-
氨基嘧啶-4-基)
氨基)苯基)-2-(5-(4-(4-甲基
哌嗪-1-基)苯基)-
1-氧代异吲哚啉-2-基)-2-苯基乙酰胺( 6q ) 。对接研究表明,顶部化合物6q跨越
EGFR的正构和变构位点,并与位于两个位点的残基Asp855、Lys745和Met793形成三个关键的氢键。
生物学评价表明,化合物6q对Ba/F3-
EGFR L858R/T790M/C797S和Ba/F3-
EGFR Del19/T790M/C797S细胞显示出潜在的抑制活性,IC 50值分别为0.42 μM和0.41 μM。此外,化合物6q对突变型NSCLC
细胞系NCI–H1975-
EGFR L858R/T790M/C797S细胞表现出优异的活性,IC